Drug Trial Radar · NCT07095127
Safety, Tolerability, and Efficacy of NVG-2089 in Participants With Immune Thrombocytopenia
Last checked: Nov 20, 2026Latest source record: Sep 14, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
30
Planned (sponsor's estimate)
Start
Sep 30, 2025
Primary completion
Jun 30, 2027
Study completion Dec 31, 2027
Sponsor
- Lead sponsor
- Nuvig Therapeutics, Inc.Industry
- Sponsor type
- Industry
- First posted
- Jul 31, 2025
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 80 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of the study is to evaluate the safety of NVG-2089 and to evaluate how well patients respond to this investigational treatment. NVG-2089 is a new drug that is being developed for treating patients with ITP. NVG-2089 is designed to mimic the effects of a protein called IVIg. NVG-2089 is designed to help the immune system by attaching (binding) to certain receptors in the body and activating them, which helps reduce inflammation and supports how the immune system works.
Conditions
- Immune Thrombocytopenia (ITP)
Interventions
NVG-2089Drug
Study Treatment
Primary outcomes
What the sponsor says the trial is designed to measure.
- Evaluate incidence, nature and severity of Treatment Emergent Adverse Events (TEAEs)Time frame: From enrollment to end of treatment Week 20
- Evaluate incidence, nature and severity of Serious Adverse Events (SAEs)Time frame: From enrollment to end of treatment Week 20
Locations
3 sites in 1 country. Site status is shown where the registry gives one.
Georgetown University Medical Center
Washington D.C., District of Columbia · Recruiting
Beth Israel Deaconess Medical Center
Boston, Massachusetts · Recruiting
East Carolina University
Greenville, North Carolina · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.